Edmond DE Rothschild Holding S.A. Takes $550,000 Position in Edwards Lifesciences Corporation $EW

Edmond DE Rothschild Holding S.A. acquired a new position in Edwards Lifesciences Corporation (NYSE:EW) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund acquired 6,084 shares of the medical research company’s stock, valued at approximately $550,000.

Several other large investors have also recently modified their holdings of EW. MV Capital Management Inc. purchased a new stake in Edwards Lifesciences during the fourth quarter valued at approximately $26,000. Hanson & Doremus Investment Management purchased a new position in Edwards Lifesciences in the first quarter worth $25,000. Kemnay Advisory Services Inc. acquired a new position in shares of Edwards Lifesciences during the fourth quarter worth $27,000. JPL Wealth Management LLC acquired a new position in shares of Edwards Lifesciences during the third quarter worth $25,000. Finally, Hilton Head Capital Partners LLC purchased a new stake in shares of Edwards Lifesciences during the 4th quarter valued at $28,000. Institutional investors own 79.46% of the company’s stock.

Insider Buying and Selling at Edwards Lifesciences

In other news, VP Donald E. Bobo, Jr. sold 23,145 shares of the firm’s stock in a transaction dated Wednesday, May 27th. The stock was sold at an average price of $86.42, for a total value of $2,000,190.90. Following the completion of the transaction, the vice president directly owned 98,611 shares in the company, valued at $8,521,962.62. This trade represents a 19.01% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, SVP Andrew M. Dahl sold 568 shares of Edwards Lifesciences stock in a transaction dated Friday, May 29th. The stock was sold at an average price of $86.08, for a total value of $48,893.44. Following the sale, the senior vice president directly owned 15,334 shares of the company’s stock, valued at $1,319,950.72. This trade represents a 3.57% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 25,570 shares of company stock worth $2,219,390. 0.31% of the stock is currently owned by insiders.

Edwards Lifesciences Trading Down 2.4%

NYSE:EW opened at $90.02 on Friday. Edwards Lifesciences Corporation has a 12 month low of $72.30 and a 12 month high of $96.29. The firm has a fifty day simple moving average of $89.12 and a 200-day simple moving average of $84.63. The company has a current ratio of 4.52, a quick ratio of 3.77 and a debt-to-equity ratio of 0.06. The company has a market capitalization of $51.83 billion, a P/E ratio of 51.74, a PEG ratio of 2.32 and a beta of 0.85.

Edwards Lifesciences (NYSE:EW) last released its earnings results on Thursday, July 23rd. The medical research company reported $0.78 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.74 by $0.04. Edwards Lifesciences had a return on equity of 15.68% and a net margin of 15.43%.The firm had revenue of $1.74 billion for the quarter, compared to the consensus estimate of $1.70 billion. During the same period in the prior year, the firm earned $0.67 EPS. The firm’s revenue was up 13.6% on a year-over-year basis. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. On average, equities research analysts anticipate that Edwards Lifesciences Corporation will post 3 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on EW shares. Barclays reissued an “overweight” rating and issued a $110.00 price objective (up from $104.00) on shares of Edwards Lifesciences in a research report on Monday, April 27th. Royal Bank Of Canada increased their price target on Edwards Lifesciences from $100.00 to $110.00 and gave the company an “outperform” rating in a research note on Monday, July 13th. Wall Street Zen cut Edwards Lifesciences from a “buy” rating to a “hold” rating in a research note on Saturday, July 4th. Mizuho raised their price target on Edwards Lifesciences from $100.00 to $105.00 and gave the stock an “outperform” rating in a report on Wednesday, July 15th. Finally, Citigroup boosted their price target on Edwards Lifesciences from $101.00 to $110.00 and gave the stock a “buy” rating in a research note on Wednesday, July 8th. Seventeen investment analysts have rated the stock with a Buy rating and six have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $100.27.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.